169237-62-1Relevant academic research and scientific papers
IIB/IIIA ANTAGONISTS CO-ADMINISTERED WITH ASPIRIN
-
, (2008/06/13)
The present invention is directed to coadministration of the fibrinogen receptor antagonists 3S-[[4-[[4-aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentynoic acid or ethyl 3S-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-penty
Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonists
Zablocki,Rico,Garland,Rogers,Williams,Schretzman,Rao,Bovy,Tjoeng,Lindmark,Toth,Zupec,McMackins,Adams,Miyano,Markos,Milton,Paulson,Herin,et al.
, p. 2378 - 2394 (2007/10/02)
Our initial orally active fibrinogen receptor antagonist benzamidinopentanoyl (BAP) series which was discovered through truncation of our iv antiplatelet agent (SC-52012) demonstrated modest oral activity in canine studies (ethyl [5-(4-amidinophenyl)penta
Substituted β-amino acid derivatives useful as platelet aggregation inhibitors
-
, (2008/06/13)
Novel substituted β amino acid derivatives are provided which inhibit platelet aggregation. This invention also pertains to pharmaceutical compositions and methods of using such derivatives.
Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof
-
, (2008/06/13)
Novel substituted β amino acid derivatives are provided which inhibit platelet aggregation and intermediates thereof. This invention also pertains to pharmaceutical compositions and methods of using such derivatives.
